Curaleaf (CURA) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
22 Jun, 2026Opening remarks and agenda
Meeting held virtually to enhance shareholder participation and accessibility, with clear rules for orderly conduct and voting procedures established.
Attendees were informed about the use of technology for voting and Q&A, and the agenda was set out in the management information circular.
Quorum was confirmed, and the meeting was declared duly constituted for business.
Board and executive committee updates
Seven directors were proposed for election, including two new nominees, with one director not standing for re-election.
The number of directors was set at 10, with the board empowered to fill three vacancies.
All seven nominees were elected to serve until the next AGM or until successors are appointed.
Shareholder proposals
Shareholders considered resolutions on the Stock and Incentive Plan, amendment to share capital, option RSU exchange, and a plan of arrangement for U.S. continuation.
Each proposal was explained, including voting requirements and implications.
Latest events from Curaleaf
- Q2 2026 revenue rose 10% to $340M, with $12.5M net income and strong international growth.CURA
Q2 2026 - Q1 2026 revenue rose 6% to $324M, with $70M net income and strong global expansion.CURA
Q1 2026 - Q4 2025 revenue hit $333M, margins improved, and international revenue grew 65% year-over-year.CURA
Q4 2025 - Six directors elected, board set at 10, and auditor appointed with no shareholder questions.CURA
AGM 2025 - Q3 revenue hit $320M, with 56% international growth and improved margins despite price pressure.CURA
Q3 2025 - Q3 saw $331M revenue, 49% gross margin, and 82% international growth amid U.S. headwinds.CURA
Q3 2024 - Q2 revenue up 2% to $342M, with 78% international growth and 48% adjusted gross margin.CURA
Q2 2024 - Board size set at 10, all directors and auditor approved, with no questions from shareholders.CURA
AGM 2024 - 2024 revenue flat at $1.34B; international sales up 73% and margins improved.CURA
Q4 2024